Katsuhiko Yanaga

Sanno Medical Center — Japan

Medicine · Health Sciences

59h-index16.3kcitations1.2kworks3.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Pancreatic and Hepatic Oncology Research(144), Gastric Cancer Management and Outcomes(133), Organ Transplantation Techniques and Outcomes(123), Esophageal and GI Pathology(121), Liver Disease and Transplantation(102)

Publications1.2k total

A Case of Idiopathic Appendiceal Intussusception Difficult to Distinguish from an Appendiceal Tumor
Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association)·2024Open Access
Supplementary figure S1 from Mechanisms of Overcoming Intrinsic Resistance to Gemcitabine in Pancreatic Ductal Adenocarcinoma through the Redox Modulation
2023Open Access
Supplementary figure S3 from Mechanisms of Overcoming Intrinsic Resistance to Gemcitabine in Pancreatic Ductal Adenocarcinoma through the Redox Modulation
2023Open Access
Supplementary figure S1 from Mechanisms of Overcoming Intrinsic Resistance to Gemcitabine in Pancreatic Ductal Adenocarcinoma through the Redox Modulation
2023Open Access
Supplementary Table S1 from Mechanisms of Overcoming Intrinsic Resistance to Gemcitabine in Pancreatic Ductal Adenocarcinoma through the Redox Modulation
2023Open Access
Supplementary figure S2 from Mechanisms of Overcoming Intrinsic Resistance to Gemcitabine in Pancreatic Ductal Adenocarcinoma through the Redox Modulation
2023Open Access
Supplementary figure S4 from Mechanisms of Overcoming Intrinsic Resistance to Gemcitabine in Pancreatic Ductal Adenocarcinoma through the Redox Modulation
2023Open Access
Supplementary figure S3 from Mechanisms of Overcoming Intrinsic Resistance to Gemcitabine in Pancreatic Ductal Adenocarcinoma through the Redox Modulation
2023Open Access
Data from Mechanisms of Overcoming Intrinsic Resistance to Gemcitabine in Pancreatic Ductal Adenocarcinoma through the Redox Modulation
2023Open Access
Supplementary information from Mechanisms of Overcoming Intrinsic Resistance to Gemcitabine in Pancreatic Ductal Adenocarcinoma through the Redox Modulation
2023Open Access
Supplementary figure S2 from Mechanisms of Overcoming Intrinsic Resistance to Gemcitabine in Pancreatic Ductal Adenocarcinoma through the Redox Modulation
2023Open Access
Data from Mechanisms of Overcoming Intrinsic Resistance to Gemcitabine in Pancreatic Ductal Adenocarcinoma through the Redox Modulation
2023Open Access
Supplementary figure S4 from Mechanisms of Overcoming Intrinsic Resistance to Gemcitabine in Pancreatic Ductal Adenocarcinoma through the Redox Modulation
2023Open Access
Supplementary Table S1 from Mechanisms of Overcoming Intrinsic Resistance to Gemcitabine in Pancreatic Ductal Adenocarcinoma through the Redox Modulation
2023Open Access
Supplementary information from Mechanisms of Overcoming Intrinsic Resistance to Gemcitabine in Pancreatic Ductal Adenocarcinoma through the Redox Modulation
2023Open Access
Supplementary Figure 3 from Pomalidomide Inhibits PD-L1 Induction to Promote Antitumor Immunity
2023Open Access
Supplementary Figure 3 from Pomalidomide Inhibits PD-L1 Induction to Promote Antitumor Immunity
2023Open Access
Supplementary Figure 7 from Pomalidomide Inhibits PD-L1 Induction to Promote Antitumor Immunity
2023Open Access
Supplementary Figure 4 from Pomalidomide Inhibits PD-L1 Induction to Promote Antitumor Immunity
2023Open Access
Supplementary Figure 7 from Pomalidomide Inhibits PD-L1 Induction to Promote Antitumor Immunity
2023Open Access
page 1 of 61Next →

Frequent Co-authors

Mitsuo Shimada(10), Ken Shirabe(7), Keizō Sugimachi(6), Tomonobu Gion(6), Kiyoshi Kajiyama(6), K Sugimachi(6), K Takenaka(5), Mitsuyoshi Urashima(4), Koshi Mimori(4), Takashi Maeda(4), Kenji Takenaka(4), Takeshi Takahara(3), Michiaki Unno(3), Norio Mitsumori(3), Fumiaki Tanaka(3), Hiroshi Inoue(3), Y Fujiwara(3), Andreas G. Tzakis(3), L Makowka(3), Hiroaki Shiba(3)